Exomic sequencing of the glutamate receptor, ionotropic, N-methyl-D-aspartate 3A gene (GRIN3A) reveals no association with schizophrenia

被引:15
|
作者
Shen, Yu-Chih [2 ,3 ]
Liao, Ding-Lieh [1 ,4 ]
Chen, Jen-Yeu [5 ]
Wang, Ying-Chieh [5 ]
Lai, I-Ching [5 ]
Liou, Ying-Jay [8 ]
Chen, Yu-Jun [6 ]
Luu, Sy-Ueng [9 ]
Chen, Chia-Hsiang [1 ,2 ,7 ]
机构
[1] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Mental Hlth & Addict Med, Zhunan 350, Taiwan
[2] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan
[3] Tzu Chi Med Ctr & Univ, Dept Psychiat, Hualien, Taiwan
[4] Bali Psychiat Ctr, Dept Hlth, Taipei, Taiwan
[5] Yuli Vet Hosp, Dept Psychiat, Hualien, Taiwan
[6] Hualien Armed Forced Gen Hosp, Hualien, Taiwan
[7] Tzu Chi Univ, Grad Inst Clin Med, Hualien, Taiwan
[8] Vet Gen Hosp, Dept Psychiat, Taipei, Taiwan
[9] Taoyuan Armed Forced Gen Hosp, Dept Psychiat, Tao Yuan, Taiwan
关键词
Schizophrenia; NMDAR; NR3A; GRIN3A; Rare mutations; Pathogenesis; SINGLE-NUCLEOTIDE POLYMORPHISMS; SYNONYMOUS MUTATIONS; NR1; SUBUNIT; NMDA; NR3A; EXPRESSION; GPS2; COMPLEX; CLONING; IDENTIFICATION;
D O I
10.1016/j.schres.2009.07.005
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Growing evidence suggests that dysregulation of N-methyl-D-aspartate receptor (NMDAR)-mediated glutamate neurotransmission may be involved in the pathophysiology of schizophrenia. The NMDAR is a heteromeric protein complex consisting of subunits from three subfamilies (NR1, NR2A, 2B, 2C, 2D and NR3A, 3B). The unique ability of NR3A to modulate the NMDAR function makes it an attractive candidate gene of schizophrenia. The purpose of this study was to investigate the involvement of the gene encoding the human NR3A subunit (GRIN3A) in the liability to schizophrenia. Methods: We searched for genetic variants in the putative core promoter region and all the exons (including UTR ends) of the GRIN3A gene in 333 Han Chinese patients with schizophrenia and 369 control subjects from Taiwan using direct polymerase chain reaction (PCR) autosequencing, and assessed their association with schizophrenia. Results: We identified 22 single nucleotide polymorphisms (SNPs) in the GRIN3A gene in this sample. SNP- and haplotype-based analyses showed no association of these 22 SNPs with schizophrenia. Nevertheless, we identified two missense mutations (D133N and Q1091H), one nonsense mutation (R1024X), and two synonymous mutations (Y873Y and E889E) of the GRIN3A gene in 6 out of 333 (1.8%) patients, while no rare mutations were found in 369 control subjects (p = 0.011, Fisher's exact test, one-tailed). In silico analysis showed that the R1024X and Q-1091H mutations are possibly damaging. Conclusions: Although the functional significance of these mutations remains to be characterized, our study indicates that rare mutations in the GRIN3A gene may contribute to the pathogenesis of schizophrenia in certain patients. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 50 条
  • [21] Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia
    Nudmamud, S
    Reynolds, GP
    NEUROSCIENCE LETTERS, 2001, 304 (1-2) : 9 - 12
  • [22] ORGANIZATION OF N-METHYL-D-ASPARTATE GLUTAMATE-RECEPTOR GENE-EXPRESSION IN THE BASAL GANGLIA OF THE RAT
    STANDAERT, DG
    TESTA, CM
    YOUNG, AB
    PENNEY, JB
    JOURNAL OF COMPARATIVE NEUROLOGY, 1994, 343 (01) : 1 - 16
  • [23] An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray
    Shengying Qin
    Xu Zhao
    Yuxi Pan
    Jianhua Liu
    Guoyin Feng
    Jingchun Fu
    Jiying Bao
    Zhizhou Zhang
    Lin He
    European Journal of Human Genetics, 2005, 13 : 807 - 814
  • [24] An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray
    Qin, SY
    Zhao, X
    Pan, YX
    Liu, JH
    Feng, GY
    Fu, JC
    Bao, JY
    Zhang, ZZ
    He, L
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (07) : 807 - 814
  • [25] Neurophysiological Mechanisms of Cortical Learning Plasticity Impairments in Schizophrenia and Modulation by the N-Methyl-D-Aspartate Type Glutamate Receptor Agonist D-Serine
    Kantrowitz, Joshua
    Epstein, Michael
    Beggel, Odeta
    Rohrig, Stephanie
    Lehrfeld, Jonathan
    Revheim, Nadine
    Lehrfeld, Nayla
    Reep, Jacob
    Parker, Emily
    Silipo, Gail
    Ahissar, Merav
    Javitt, Daniel
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S174 - S175
  • [26] Classification of missense variants in the N-methyl-d-aspartate receptor GRIN gene family as gain- or loss-of-function
    Myers, Scott J.
    Yuan, Hongjie
    Perszyk, Riley E.
    Zhang, Jing
    Kim, Sukhan
    Nocilla, Kelsey A.
    Allen, James P.
    Bain, Jennifer M.
    Lemke, Johannes R.
    Lal, Dennis
    Benke, Timothy A.
    Traynelis, Stephen F.
    HUMAN MOLECULAR GENETICS, 2023, 32 (19) : 2857 - 2871
  • [27] Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia
    Jadi, Monika P.
    Behrens, M. Margarita
    Sejnowski, Terrence J.
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 716 - 726
  • [28] Association Study of N-Methyl-D-Aspartate Receptor Subunit 2B (GRIN2B) Polymorphisms and Schizophrenia Symptoms in the Han Chinese Population
    Yang, Yongfeng
    Li, Wenqiang
    Zhang, Hongxing
    Yang, Ge
    Wang, Xiujuan
    Ding, Minli
    Jiang, Tianzi
    Lv, Luxian
    PLOS ONE, 2015, 10 (05):
  • [29] Evaluation of natural and nitramine binding energies to 3-D models of the S1S2 domains in the N-methyl-D-aspartate receptor
    Ford-Green, Jason
    Isayev, Olexandr
    Gorb, Leonid
    Perkins, Edward J.
    Leszczynski, Jerzy
    JOURNAL OF MOLECULAR MODELING, 2012, 18 (04) : 1273 - 1284
  • [30] Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
    Meltzer, Herbert Y.
    Rajagopal, Lakshmi
    Huang, Mei
    Oyamada, Yoshihiro
    Kwon, Sunoh
    Horiguchi, Masakuni
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (10) : 2181 - 2194